In 2021, the market was estimated at a $34,748.18 million valuation.
There are several key players in the global GI market who are expected to continue dominating the market going forward, including AstraZeneca, Pfizer, Teva and Abbot.
The GI market includes medications and services used for treatment of illnesses including Crohn’s, IBS and colitis.
The report also covers growth in the market across North America, Europe, Asia-Pacific, South America, and the Middle East and Africa.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
